Pde1C Protein — Phosphodiesterase 1C is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Phosphodiesterase 1C |
|---|
| Protein Name | PDE1C |
| Gene | PDE1C |
| UniProt ID | Q14139 |
| PDB Structure | 6X4O, 5JOX |
| Molecular Weight | 87 kDa |
| Subcellular Localization | Cytoplasm, membrane-associated |
| Brain Expression | Widespread in cortex, hippocampus, cerebellum |
PDE1C (Phosphodiesterase 1C, encoded by the PDE1C gene) is a calcium/calmodulin-dependent phosphodiesterase that hydrolyzes both cAMP and cGMP. It is one of the most abundant phosphodiesterases in the brain and plays crucial roles in synaptic plasticity, memory formation, and neuronal survival.
PDE1C provides a critical link between calcium signaling and cyclic nucleotide pathways, making it a key regulator of neuronal function and a potential therapeutic target for neurodegenerative diseases.
PDE1C contains several functional domains:
- N-terminal regulatory domain: Contains calmodulin-binding motifs
- EF-hand motifs: Two calcium-binding motifs for calmodulin activation
- C-terminal catalytic domain: Contains PDE signature motifs for hydrolysis
- Dimerization interface: Enables formation of functional dimers
PDE1C hydrolyzes:
- Activated by calcium/calmodulin complex
- Provides link between calcium signaling and cAMP/cGMP regulation
- Allows integration of multiple signaling pathways in neurons
- Synaptic plasticity: Modulates cAMP/cGMP levels at synapses
- Memory formation: Critical for hippocampal-dependent learning
- Neuronal excitability: Regulates ion channel function through cyclic nucleotides
PDE1C involvement in Alzheimer's disease:
- Memory impairment: PDE1C inhibition improves memory in AD models[^1]
- Amyloid-beta effects: Amyloid-beta reduces PDE1C activity, disrupting cAMP signaling[^2]
- Therapeutic potential: PDE1 inhibitors show promise in AD preclinical studies
In Parkinson's disease:
- Dopaminergic signaling: PDE1C regulates cAMP in dopaminergic neurons[^3]
- Neuroprotection: PDE1 inhibition protects against MPTP toxicity
- Levodopa response: May modulate response to dopaminergic therapy
In Huntington's disease:
- cAMP signaling: PDE1C alterations affect mutant huntingtin function
- Therapeutic targeting: PDE1 inhibitors under investigation
In ALS:
PDE1C is a promising drug target for neurodegenerative diseases:
- Vinpocetine: Traditional PDE1 inhibitor, studied for cognitive enhancement
- IC86340: Selective PDE1 inhibitor
- KR-36996: Potent PDE1 inhibitor with neuroprotective effects
- Cognitive enhancement in aging and dementia
- Neuroprotection in Parkinson's disease
- Adjunct therapy in depression and ADHD
¶ Interactions and Signaling Pathways
PDE1C interacts with:
- Calmodulin (activation)
- cAMP-dependent protein kinase (PKA)
- cGMP-dependent protein kinase (PKG)
- CREB transcription factor
- Various ion channels
The study of Pde1C Protein — Phosphodiesterase 1C has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PDE1 inhibition improves memory in Alzheimer's disease models (PMID: 20452377)
- Amyloid-beta effects on phosphodiesterase signaling (PMID: 19158546)
- PDE1 in dopaminergic neuron function and Parkinson's disease (PMID: 23474447)
- Calcium-calmodulin phosphodiesterases in the brain (PMID: 10517883)
- PDE1 inhibitors as therapeutic agents for neurodegenerative diseases (PMID: 25880023)